Premium
High Serum Prolactin Associated with Poor Prognosis in Carcinoma of the Prostate
Author(s) -
MEE A. D.,
KHAN O.,
MASHITER K.
Publication year - 1984
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1984.tb06150.x
Subject(s) - prolactin , medicine , orchiectomy , prostate carcinoma , prostate , carcinoma , urology , endocrinology , oncology , hormone , cancer
Summary— Seventy patients with carcinoma of the prostate have had regular estimations of serum prolactin levels during a 10‐month period, and were followed up for a further 6 months. Of 21 patients who recorded at least one high serum prolactin, 10 (48%) died during these 16 months, while of 50 with normal prolactin, only 2 (4%) died. Ten (21%) of the 47 patients on oestrogen or anti‐androgen therapy died, and 9 of these had a high prolactin. This contrasts with 2 (14%) deaths of 14 who had had either bilateral orchiectomy or radiotherapy to the prostate. One of the 2 who died had a high prolactin. It is concluded that an elevated serum prolactin in treated carcinoma of the prostate is associated with progression of the disease and a poor prognosis.